Disease relevance of Angina Pectoris, Variant

• Nifedipine antagonises influx of calcium through cell membrane slow channels, and sustained release formulations of the calcium channel blocker have been shown to be effective in the treatment of mild to moderate hypertension and both stable and variant angina pectoris [1].
• Comparison of plasma serotonin levels in patients with variant angina pectoris versus healed myocardial infarction [2].
• Stenoses that seem to be fixed in patients with Prinzmetal's angina should be suspected to be spasm even if unresponsive to nitroglycerin, especially when the rest of the vessel is normal [3].
• We report a patient with Prinzmetal's angina with nearly normal coronary angiogram who not only developed severe myocardial ischemia during exercise, documented both electrocardiographically (ST elevation) and scintigraphically (with thallium-201), but also did so intermittently as the graded exercise progressed [4].

High impact information on Angina Pectoris, Variant

• To assess the efficacy and safety of verapamil in variant angina pectoris, we entered 16 patients in a double-blind, randomized trial of nine months, duration [5].
• Mouse model of Prinzmetal angina by disruption of the inward rectifier Kir6.1 [6].
• Variant angina pectoris associated with moyamoya disease [7].
• Provocation of coronary spasm by dopamine in patients with active variant angina pectoris [8].
• Elevation of thromboxane B2 levels in patients with classic and variant angina Pectoris [9].

Chemical compound and disease context of Angina Pectoris, Variant

• Nifedipine therapy for Prinzmetal's angina [10].
• Clinical observation of spontaneous anginal attacks and multivessel spasm in variant angina pectoris with normal coronary arteries: evaluation by 24-hour 12-lead electrocardiography with computer analysis [11].
• Multiclinic controlled trial of diltiazem for Prinzmetal's angina [12].
• Effect of a new coronary vasodilator, nicorandil, on variant angina pectoris [13].
• Prinzmetal's angina during cyclophosphamide therapy [14].

Biological context of Angina Pectoris, Variant

• Despite the increasing evidence that alterations in coronary vascular tone can and do occur in patients with anginal syndromes, only in a minority of such patients with Prinzmetal's angina is there decisive evidence that the coronary vasodilation induced by calcium channel antagonists (CCAs) plays a specific therapeutic role [15].
• Effect of verapamil and nifedipine on left ventricular function at rest and during exercise in patients with Prinzmetal's variant angina pectoris [16].
• Thus, calcium ions appear to have a different role in the coronary smooth muscle contractility of the 2 series of patients; in fact, in Prinzmetal's angina nifedipine relaxed the coronary arteries to a greater degree and made them unresponsive to stimuli that were still able to cause vasoconstriction in patients with syndrome X [17].
• A retrosepctive evaluation has been made of blood pressure, pulse rate, and number of anginal attacks per day in twenty-one patients diagnosed as Prinzmetal's Angina and treated with the investigational drug nifedipine [18].

Gene context of Angina Pectoris, Variant

• In addition, the Kir6.1 null mouse is a model of Prinzmetal angina in humans [19].
• Suppression of hyperventilation-induced attacks with infusion of atrial natriuretic peptide in patients with variant angina pectoris [20].
• Decrease in plasma adiponectin concentrations in patients with variant angina pectoris [21].

Analytical, diagnostic and therapeutic context of Angina Pectoris, Variant

• Efficacy of chronic amiodarone therapy in patients with variant angina pectoris and inhibition of ergonovine coronary constriction [22].
• Patients with Prinzmetal angina, who were known to have homogeneous coronary vasodilating reactions and favorable clinical responses to nifedipine, were studied by means of the same methods and served as the control group (14 patients) [23].

References